Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework
Abstract
:1. Introduction
2. Materials and Methods
2.1. Sample Collection and Processing
2.2. The Application of the BlueStain Method
2.3. Cytological Microscopic Evaluation
- -
- Background: The slide background is clear and free of artifacts or unwanted staining that could obscure cellular details.
- -
- Overall stain: The staining is appropriate in intensity, enhancing the visibility of cellular structures without overpowering or under-representing any features.
- -
- Cellularity: The specimen contains an ample number of cells with the staining uniformly distributed along the slide.
- -
- Cell morphology: Cells maintain typical morphology with well-preserved structures, facilitating easy identification and classification.
- -
- Cytoplasmic details: The cytoplasm of cells is clearly visible and shows distinct boundaries and internal structures where applicable.
- -
- Nuclear characteristics: Nuclear contours are sharp; nuclei are appropriately sized and shaped, with any physiological variations clearly discernible.
- -
- Cellular pleomorphism: Variation in cell size and shape is minimal, reflecting a homogeneous cell population or the expected heterogeneity in reactive or neoplastic conditions.
- -
- Nuclear chromatin: The chromatin pattern is distinct and evenly distributed, indicating good preservation and staining.
- -
- Nucleoli: If present, they are clearly visible and well-defined, appropriate for the cell type and pathological state.
- -
- Background: The slide background shows minor artifacts or staining issues, but these do not significantly hinder the observation of cellular features.
- -
- Overall stain: Staining is generally adequate though may be uneven in some areas, with some cellular features less clearly highlighted.
- -
- Cellularity: The cell density is moderate, with the staining not completely uniformly distributed along the slide.
- -
- Cell morphology: Some cell structures are slightly distorted or less distinctly preserved, posing minor challenges to identification.
- -
- Cytoplasmic details: Cytoplasmic boundaries and contents are visible but may lack sharpness or detail.
- -
- Nuclear characteristics: Nuclear details are reasonably clear; however, slight blurring or irregularities in size and shape may be present.
- -
- Cellular pleomorphism: There is noticeable variability in cell size and shape, which may slightly complicate the evaluation.
- -
- Nuclear chromatin: Chromatin is visible but may show some clumping or irregular distribution.
- -
- Nucleoli: Nucleoli are discernible but may lack crisp definition or uniform appearance.
- -
- Background: The background is cluttered with artifacts or excessive staining, significantly obstructing cellular detail observation.
- -
- Overall stain: Staining is poor, either too faint or overly intense, obscuring critical cellular features.
- -
- Cellularity: The cell density is sparse or moderate, with the heterogeneous distribution of the staining along the slide.
- -
- Cell morphology: Cell structures are poorly preserved or markedly distorted, making reliable identification challenging.
- -
- Cytoplasmic details: Cytoplasmic features are blurred or indistinguishable, with poor definition of internal and boundary structures.
- -
- Nuclear characteristics: Nuclei are poorly defined, overstained and without clear details on chromatin and nucleoli.
- -
- Cellular pleomorphism: High variability in cell size and shape is present, exceeding expected norms and complicating analysis.
- -
- Nuclear chromatin: Chromatin appears smeared, overly clumped, or unevenly distributed, detracting from diagnostic accuracy.
- -
- Nucleoli: Nucleoli, if visible, are poorly defined or irregular, providing little diagnostic value.
2.4. Quality Index Calculation
2.5. Resolution of Discordant Scores
2.6. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Test | p-Value |
---|---|
BlueStain vs. Papanicolaou stain | 0.9241 |
BlueStain vs. Giemsa stain | 0.0005 |
Papanicolaou stain vs. Giemsa stain | <0.0001 |
Test | p-Value | |||
---|---|---|---|---|
Atypical | Benign | Suspicious for Malignancy | Malignant | |
BlueStain vs. Papanicolaou stain | 1.0000 | 1.0000 | 1.0000 | 0.3651 |
BlueStain vs. Giemsa stain | 1.0000 | 0.0512 | 1.0000 | 0.0101 |
Papanicolaou stain vs. Giemsa stain | 1.0000 | 0.0178 | 1.0000 | 0.0001 |
Test | p-Value | ||
---|---|---|---|
Blue Stain | Papanicolaou Stain | Giemsa Stain | |
Atypical vs. Benign | 1.0000 | 1.0000 | 1.0000 |
Atypical vs. Suspicious for Malignancy | 1.0000 | 0.6751 | 1.0000 |
Atypical vs. Malignant | 0.0367 | 0.0056 | 1.0000 |
Benign vs. Suspicious for Malignancy | 1.0000 | 1.0000 | 1.0000 |
Benign vs. Malignant | 0.0039 | 0.0005 | 1.0000 |
Suspicious for Malignancy vs. Malignant | 0.2584 | 0.9834 | 1.0000 |
References
- Pinto, D.; Chandra, A.; Crothers, B.; Kurtycz, D.; Schmitt, F. The international system for reporting serous fluid cytopathology—Diagnostic categories and clinical management. J. Am. Soc. Cytopathol. 2020, 9, 469–477. [Google Scholar] [CrossRef]
- Lobo, C.; Costa, J.; Petronilho, S.; Monteiro, P.; Leça, L.; Schmitt, F. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center. Diagn. Cytopathol. 2021, 49, 96–605. [Google Scholar] [CrossRef]
- Sachan, R.; Gupta, A.; Awasthi, P.N.; Singh, P.; Anand, N.; Chandra, S.; Gaur, G.; Husain, N.; Sachan, K.D. Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples—A prospective study in an oncology setting. J. Am. Soc. Cytopathol. 2023, 12, 351–361. [Google Scholar] [CrossRef]
- Altman, E.; Spiridonov, L.; Vadim, S.; Alejandro, L.; Alexei, G.; Hector, C.I. Efficacy of cytology, cell blocks and thoracoscopic pleural biopsy in malignant pleural effusion diagnosis. Eur. Respir. J. 2013, 42, P3073. [Google Scholar]
- Lu, C.; Liu, C.; Jhuang, J.Y.; Chen, C. Comprehensive evaluation of benign and malignant etiologies of different serous effusions with the International System for Reporting Serous Fluid Cytopathology: A multi-institutional study in Taiwan. Cancer Cytopathol. 2024, 132, 169–178. [Google Scholar] [CrossRef]
- Schmitt, F.; Bubendorf, L.; Canberk, S.; Chandra, A.; Cree, I.; Engels, M.; Hiroshima, K.; Jain, D.; Kholová, I.; Layfield, L.; et al. The World Health Organization Reporting, System for Lung Cytopathology. Acta Cytol. 2023, 67, 80–91. [Google Scholar] [CrossRef]
- Ali, S.Z.; Baloch, Z.W.; Cochand-Priollet, B.; Schmitt, F.C.; Vielh, P.; VanderLaan, P.A. The 2023 Bethesda System for Reporting Thyroid Cytopathology. J. Am. Soc. Cytopathol. 2023, 12, 319–325. [Google Scholar] [CrossRef]
- Nayar, R.; Wilbur, D. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes; Springer: Berlin/Heidelberg, Germany, 2015. [Google Scholar]
- Deepthi, B.; Prayaga, A.K.; Rukmangadha, N. Comparison of modified ultrafast giemsa stain with the standard may grunwald giemsa stain in FNAC of various organs. J. Cytol. 2022, 39, 174–179. [Google Scholar] [CrossRef]
- Paessler, M.; LiVolsi, V.A.; Baloch, Z.W. Role of ultrafast papanicolaou-stained scrape preparations as an adjunct to frozen sections in the surgical management of thyroid lesions. Endocr. Pract. 2001, 7, 89–94. [Google Scholar] [CrossRef]
- Vidal, B.; Mello, M.L. Toluidine blue staining for Cell and tissue biology applications. Acta Histochem. 2019, 121, 101–112. [Google Scholar] [CrossRef]
- Alves, P.M.; Ferreira, F.; Oliveira, T.; Alves, D.; Canberk, S.; Schmitt, F.C. A New Cytology Staining Method: A Fast Approach for Rapid On-Site Evaluation on Thyroid Fine-Needle Aspiration Cytology. Acta Cytol. 2023, 67, 289–294. [Google Scholar] [CrossRef] [PubMed]
- Chantziantoniou, N.; Donnelly, A.D.; Mukherjee, M.; Boon, M.; Austin, R.M. Inception and Development of the Papanicolaou Stain Method. Acta Cytol. 2017, 61, 266–280. [Google Scholar] [CrossRef] [PubMed]
- VandenBussche, C.; Crothers, B.; Chandra, A.; Schmitt, F.; Kurtycz, D. The International System for Reporting Serous Fluid Cytopathology: The Initial Project Survey. Cytopathology 2023, 34, 191–197. [Google Scholar] [CrossRef] [PubMed]
- Thakur, M.; Guttikonda, V.R. Modified ultrafast Papanicolaou staining technique: A comparative study. J. Cytol. 2017, 34, 149–153. [Google Scholar] [CrossRef] [PubMed]
- Ammanagi, A.S.; Dombale, V.D.; Patil, S.S. On-site toluidine blue staining and screening improves efficiency of fine-needle aspiration cytology reporting. Acta Cytol. 2012, 56, 347–351. [Google Scholar] [CrossRef]
- Hewer, E.; Schmitt, A.M. Ultrafast Toluidine Blue Staining for Rapid On-Site Evaluation of Cytological Smears. Acta Cytol. 2020, 64, 375–377. [Google Scholar] [CrossRef]
- Grosu, H.B.; Kern, R.; Maldonado, F.; Casal, R.; Andersen, C.R.; Li, L.; Eapen, G.; Ost, D.; Jimenez, C.; Frangopoulos, F.; et al. Predicting malignant pleural effusion during diagnostic pleuroscopy with biopsy: A prospective multicentre study. Respirology 2022, 27, 350–356. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Liu, Y.; Wang, J.; Ren, T.; Luo, G.; You, H.; Wang, X.; Li, D.; Wang, L.; Wang, M. Rapid on-site evaluation of touch imprints of medical thoracoscopy biopsy tissue for the management of pleural disease. Front. Med. 2023, 10, 1196000. [Google Scholar] [CrossRef] [PubMed]
- Pinto, D.; Schmitt, F. Current applications of molecular testing on body cavity fluids. Diagn. Cytopathol. 2020, 48, 840–851. [Google Scholar] [CrossRef]
- Priyanjali, A.; Toi, P.C.; Subramaniam, H.; Lakshmi, S. Prospective comparison of cytological specimen adequacy assessment by different rapid staining techniques for rapid on-site evaluation in fine needle aspiration cytology and their cost-effectiveness. Diagn. Cytopathol. 2019, 47, 469–474. [Google Scholar] [CrossRef]
- Moya-Salazar, J.; Rojas-Zumaran, V. Eco-Pap: The Ecological Modification of the Papanicolaou Stain for Sustainable Cervical Cancer Diagnosis. Acta Cytol. 2019, 63, 35–43. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Chachra, K.L.; Bhadola, P.; Sodhani, P. Modified Papanicolaou staining protocol with minimum alcohol use: A cost-cutting measure for resource-limited settings. Cytopathology 2010, 21, 229–233. [Google Scholar] [CrossRef] [PubMed]
- Elmas, H.; Önal, B.; Steurer, S.; Hantzsch-Kuhn, B.; Claussen, M.; Mehdi, E.; Ince, Ü.; Rabe, K.F.; Sauter, G.; Welker, L. Rapid Remote Online Evaluation in Endoscopic Diagnostics: An Analysis of Biopsy-Proven Respiratory Cytopathology. Diagnostics. 2023, 13, 3329. [Google Scholar] [CrossRef] [PubMed]
BlueStain | PAP Stain | Giemsa Stain | ||
---|---|---|---|---|
Background | 1 | 48 (20.3%) | 51 (22.4%) | 32 (27.1%) |
2 | 73 (30.8%) | 50 (21.9%) | 54 (45.8%) | |
3 | 116 (48.9%) | 127 (55.7%) | 32 (27.1%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Overall stain | 1 | 45 (19.0%) | 42 (18.4%) | 32 (27.1%) |
2 | 87 (36.7%) | 70 (30.7%) | 55 (46.6%) | |
3 | 105 (44.3%) | 116 (50.9%) | 31 (26.3%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Cellularity | 1 | 88 (37.3%) | 65 (28.5%) | 56 (47.5%) |
2 | 49 (20.8%) | 42 (18.4%) | 35 (29.7%) | |
3 | 99 (41.9%) | 121 (53.1%) | 27 (22.9%) | |
Total | 236 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Cell morphology | 1 | 44 (18.6%) | 48 (21.1%) | 33 (28.0%) |
2 | 76 (32.1%) | 59 (25.9%) | 55 (46.6%) | |
3 | 117 (49.4%) | 121 (53.1%) | 30 (25.4%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Cytoplasmic details | 1 | 59 (24.9%) | 65 (28.5%) | 42 (35.6%) |
2 | 71 (30.0%) | 57 (25.0%) | 46 (39.0%) | |
3 | 107 (45.1%) | 106 (46.5%) | 30 (25.4%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Nuclear characteristics | 1 | 64 (27.0%) | 60 (26.3%) | 51 (43.2%) |
2 | 77 (32.5%) | 63 (27.6%) | 38 (32.2%) | |
3 | 96 (40.5%) | 105 (46.1%) | 29 (24.6%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Cellular pleomorphism | 1 | 49 (20.7%) | 50 (21.9%) | 35 (29.7%) |
2 | 57 (24.1%) | 57 (25.0%) | 50 (42.4%) | |
3 | 131 (55.3%) | 121 (53.1%) | 33 (28.0%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Nuclear chromatin | 1 | 67 (28.3%) | 62 (27.2%) | 53 (44.9%) |
2 | 83 (35.0%) | 64 (28.1%) | 40 (33.9%) | |
3 | 87 (36.7%) | 102 (44.7%) | 25 (21.2%) | |
Total | 237 (100.0%) | 228 (100.0%) | 118 (100.0%) | |
Nucleoli | 1 | 71 (30.0%) | 61 (26.8%) | 56 (47.9%) |
2 | 76 (32.1%) | 70 (30.7%) | 34 (29.1%) | |
3 | 90 (38.0%) | 97 (42.5%) | 27 (23.1%) | |
Total | 237 (100.0%) | 228 (100.0%) | 117 (100.0%) |
Stain | Advantages | Disadvantages | Study Focus |
---|---|---|---|
BlueStain (Current Study) | Cost-effective, rapid, effective in serous effusions | Slightly lower QI than Papanicolaou in some categories | Serous effusions using TIS system |
BlueStain [12] (Previous Study) | Lower cost, high performance in ROSE, quick preparation | Focused on thyroid FNAB samples using TBSRTC 2nd edition | Thyroid FNAB samples |
Toluidine Blue [16] (Amannagi et al.) | Rapid application, effective for ROSE in thyroid FNAB | Limited evaluation of cytomorphological features | Thyroid FNAB samples |
Toluidine Blue [17] (Hewer et al.) | Efficient in cytology reporting, quick preliminary assessments | Primarily focused on sample adequacy | Thyroid FNAB samples |
Giemsa | Detailed cellular visualization | Longer staining time, lower QI in our serous effusion study | Commonly used in cytopathology |
Papanicolaou | Highest QI, excellent detail in cellular morphology | Resource-intensive, longer processing time | Widely used in cytopathology |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alves, P.M.; Azevedo, M.T.; Ferreira, F.; Tastekin, E.; Canberk, S.; Schmitt, F.C. Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework. Diagnostics 2024, 14, 1074. https://doi.org/10.3390/diagnostics14111074
Alves PM, Azevedo MT, Ferreira F, Tastekin E, Canberk S, Schmitt FC. Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework. Diagnostics. 2024; 14(11):1074. https://doi.org/10.3390/diagnostics14111074
Chicago/Turabian StyleAlves, Paula Melo, Maria Teresa Azevedo, Fernando Ferreira, Ebru Tastekin, Sule Canberk, and Fernando C. Schmitt. 2024. "Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework" Diagnostics 14, no. 11: 1074. https://doi.org/10.3390/diagnostics14111074
APA StyleAlves, P. M., Azevedo, M. T., Ferreira, F., Tastekin, E., Canberk, S., & Schmitt, F. C. (2024). Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework. Diagnostics, 14(11), 1074. https://doi.org/10.3390/diagnostics14111074